New Inhaler for COPDers – a miracle? PATHOS StudyMarch 19th, 2013 by Sharon O'Hara
Ask your doctor…and look for a miracle inhaler for some COPDers. The PATHOS study published in the Journal of Internal Medicine shows that SYMBICORTR TurbuhalerR (budesonide/formoterol) must be some kind of miracle inhaler for chronic obstructive pulmonary disease (COPD) patients.
Among other advantages, the PATHOS study
showed a 26% decrease in exacerbations for moderate –
inhaler has to be bliss for those COPDers able to use it.
I’ve used Foradil Aerolizer
(Formoterol Fumarate Inhalation Powder) for
years. The Fulmarate
ingredient seems to make it a relative of
and it is the single inhaler I take (of
three) that noticeably helps me breathe easier.
Best of all is the promise shown in the PATHOS study:
“Dr. Kjell Larsson, Professor of Respiratory Medicine at the Karolinska
Institute in Stockholm said: “So called ‘real world’ studies, such as
PATHOS, together with randomised prospective studies, play an important role
in answering questions about the value of medicines in delivering better,
cost-effective healthcare to patients. These findings can help physicians
and the healthcare community to understand disease patterns and create a
fuller picture of treatment effects and what patients are experiencing.”
The only side-affect/warning I can find might be for asthma patients.
-16558063/ …thanks to Linda W EFFORTS <www.emphysema.net>
Thanks for listening … Sharon O’Hara < firstname.lastname@example.org
Tags: (Formoterol Fumarate Inhalation Powder, COPD, Dr. Kjell Larsson, EFFIRTS, Emphysema, healthcare, Journal of Internal Medicine, PATHOS study, patients, physcians, Professor of Respiratory Medicine at the Karolinska Institute in Stockholm, SYMBICORTR TurbuhalerR (budesonide/formoterol)